Topics:

Multiple sclerosis

Multiple sclerosis

A new study indicates that infection with Helicobacter pylori might lower the risk of multiple sclerosis, at least in women. Pharmaceutical products could provide a novel means of treatment.

The risk of progressive multifocal leukoencephalopathy in patients receiving Tysabri for MS is a concern about this otherwise extremely effective therapy.

HDIT/HCT could induce sustained remission and neurological improvements in patients with multiple sclerosis.

No evidence of disease activity (NEDA) is a new concept developing in MS. The field is beginning to ask how well the new treatments are doing and whether can we ultimately shut down the disease.

Get to the root of the latest research findings on nervous system disorders and test your brainpower with this quick 5-question quiz.

Approved for patients with relapsing forms of MS, the drug generally should be reserved for those who have had an inadequate response to 2 or more drugs indicated for MS treatment.

As more treatments become available, patients will have more preferences and will play a more prominent role in directing choices.

Pages

Subscribe to Multiple sclerosis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.